Illumina (NASDAQ:ILMN) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
Illumina (NASDAQ:ILMN) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually [Yahoo! Finance]
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Illumina (NASDAQ:ILMN) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.